Liraglutide (Victoza) vs Semaglutide (Rybelsus)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT06050577 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Victoza) | Semaglutide (Rybelsus) |
|---|---|---|
| HbA1c, change | -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
| -1.6% vs -0.2%−1.4 vs placeboNCT0410954734 other results
|
| Body weight, change (kg) | -2.3 vs 1.0−3.3 vs placeboNCT0154121522 other results
| -4.2 vs -1.3−2.9 vs placeboNCT0391432639 other results
|
| HbA1c below 7% | 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
| —Not posted · NCT07271251 |
| Fasting plasma glucose, change | -1.6 vs 1.0−2.6 vs placeboNCT0154121521 other results
| -1.9 vs -0.7−1.2 vs placeboNCT0286341939 other results
|
| 3-point MACE (% with event) | 13% vs 14.9%−1.9 vs placeboNCT01179048 | 12% vs 13.8%−1.8 vs placeboNCT039143261 other result
|
HbA1c, change
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -0.6% vs -0.5% NCT00318461
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -0.7% vs 0.7% NCT01541215
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
- Semaglutide (Rybelsus)
- -1.6% vs -0.2%−1.4 vs placeboNCT04109547
34 other results
- -1.5% vs -0.2% NCT04109547
- -1.1% vs -0.2% NCT04109547
- -0.7% vs -0.1% NCT03914326
- -1% vs -0.3% NCT02692716
- -1.2% vs -0.1% NCT02863419
- -1.2% vs -0.2% NCT03021187
- -0.9% vs -0.2% NCT03021187
- -0.6% vs -0.2% NCT03021187
- -1.5% vs 0.1% NCT03018028
- -1.4% vs 0.1% NCT03018028
- -1% vs 0.1% NCT03018028
- -1.1% vs -0.7% NCT02607865
- -1.3% vs -0.9% NCT02863328
- -1.2% vs -0.7% NCT02607865
- -0.9% vs -0.7% NCT02607865
- -1% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -1.8% vs -1.4% NCT03015220
- -2% vs -1.6% NCT03015220
- -1.4% vs -1.4% NCT03015220
- -1.7% vs -1.6% NCT03015220
- -0.8% vs -1.4% NCT03015220
- -1.1% vs -1.6% NCT03015220
- -0.2% vs 0% NCT02849080
- -1.3% vs -0.8% NCT02849080
- -2.0% vs -0.4% NCT01923181
- -1.8% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.7% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.2% vs -0.4% NCT01923181
- -0.9% vs -0.4% NCT01923181
- -1.2% vs -1.0% NCT05035082
Body weight, change (kg)
- Liraglutide (Victoza)
- -2.3 vs 1.0−3.3 vs placeboNCT01541215
22 other results
- -2.5 vs -0.9 NCT01541215
- -2.9 vs 0.7 NCT00318461
- -2.8 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- 1.2 vs 3 NCT02501161
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
- Semaglutide (Rybelsus)
- -4.2 vs -1.3−2.9 vs placeboNCT03914326
39 other results
- -4.2 vs -0.8 NCT02692716
- -4.4 vs -1 NCT02863419
- -3.8 vs 0.5 NCT03021187
- -3.1 vs -1.1 NCT04109547
- -2.2 vs 0.5 NCT03021187
- -2.9 vs -1 NCT03018028
- -0.8 vs -1 NCT03018028
- -2.2 vs -1.1 NCT04109547
- -0.9 vs 0.5 NCT03021187
- -2.4 vs -1.1 NCT03018028
- -1.2 vs -1.1 NCT03018028
- 0 vs -1 NCT03018028
- -1.1 vs -1.1 NCT04109547
- -0.4 vs -1.1 NCT03018028
- -3.2 vs -1 NCT02607865
- -4 vs -3.7 NCT02863328
- -3.5 vs -0.7 NCT02607865
- -3.8 vs -0.5 NCT04017832
- -2.8 vs -1 NCT02607865
- -2.5 vs -0.7 NCT02607865
- -2.9 vs -0.5 NCT04017832
- -1.8 vs -1 NCT02607865
- -1.6 vs -0.7 NCT02607865
- -1.7 vs 1 NCT03015220
- -2.2 vs 0.3 NCT03015220
- -0.9 vs 1 NCT03015220
- -1 vs 0.3 NCT03015220
- 0 vs 1 NCT03015220
- -1.4 vs -0.5 NCT04017832
- -0.1 vs 0.3 NCT03015220
- -2.6 vs -0.9 NCT02849080
- -6.9 vs -1.2 NCT01923181
- -5.9 vs -1.2 NCT01923181
- -8.3 vs -1.2 NCT01923181
- -5.8 vs -1.2 NCT01923181
- -4.9 vs -1.2 NCT01923181
- -2.9 vs -1.2 NCT01923181
- -2.0 vs -1.2 NCT01923181
- -3.9 vs -3.5 NCT05035082
HbA1c below 7%
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
- Semaglutide (Rybelsus)
- —Not posted · NCT07271251
Fasting plasma glucose, change
- Liraglutide (Victoza)
- -1.6 vs 1.0−2.6 vs placeboNCT01541215
21 other results
- -1.1 vs 0.8 NCT01541215
- -1.2 vs -0.6 NCT00318461
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -3.9 vs -3.7 NCT02501161
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.6 vs -3.5 NCT03172494
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
- Semaglutide (Rybelsus)
- -1.9 vs -0.7−1.2 vs placeboNCT02863419
39 other results
- -1.6 vs -0.1 NCT03021187
- -1.9 vs -0.2 NCT02906930
- -2.0 vs -0.3 NCT02863419
- -1.6 vs -0.3 NCT02827708
- -1.4 vs 0.5 NCT03021187
- -1.1 vs -0.1 NCT03021187
- -1.5 vs -0.2 NCT02906930
- -1.1 vs 0.5 NCT03021187
- -0.8 vs -0.1 NCT03021187
- -0.9 vs -0.2 NCT02906930
- -0.5 vs 0.5 NCT03021187
- -2.3 vs 0.3 NCT03018028
- -2.4 vs -0.4 NCT03018028
- -1.6 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.1 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.6 vs -0.9 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.8 vs -1.0 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.7 vs -0.9 NCT02607865
- -2 vs -0.5 NCT04017832
- -1.1 vs -0.9 NCT02607865
- -1.3 vs -1.0 NCT02607865
- -1.2 vs -0.9 NCT02607865
- -2.7 vs -2.2 NCT03015220
- -1.8 vs -0.5 NCT04017832
- -1.1 vs -0.9 NCT02607865
- -1.0 vs -1.0 NCT02607865
- -0.8 vs -0.9 NCT02607865
- -2.2 vs -1.8 NCT03015220
- -2.0 vs -1.8 NCT03015220
- -2.3 vs -2.2 NCT03015220
- -0.9 vs -1.8 NCT03015220
- -1.0 vs -0.5 NCT04017832
- -1.2 vs -2.2 NCT03015220
- -0.3 vs 0.0 NCT02849080
- -2.4 vs -1.4 NCT02849080
3-point MACE (% with event)
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Semaglutide (Rybelsus)
- 12% vs 13.8%−1.8 vs placeboNCT03914326
1 other result
- 3.8% vs 4.8% NCT02692716
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
18 other shared endpoints and safety
Coverage. Liraglutide (Victoza): 22 of 22 rows · Semaglutide (Rybelsus): 21 of 22 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) Rows use multiple source trials | Semaglutide (Rybelsus) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -1.3 vs -1.2 Oral Antidiabetic Drug kg @ 104wk1.8 mga,b,c NCT02730377 · Phase 4 · registry result, not featured evidence | -0.9 vs -0.3 Sitagliptin kg @ 104wka,b,c NCT02849080 · Phase 3 · registry result, not featured evidence |
| DBP absolute change · mmHg | -0.72 vs -1.12 placebo mmHg @ 26wkb,c NCT02964247 · Phase 3 · registry result, not featured evidence | -2 vs -2 placebo mmHg @ 26wk14 mgd,b,c NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-1 vs -2 placebo mmHg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0 vs -2 placebo mmHg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -27 vs -11.97 placebo mg @ 26wkb,c NCT02964247 · Phase 3 · registry result, not featured evidence | -32.5 vs 0 placebo mg @ 26wk14 mgd,b,c NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-32.28 vs 0 placebo mg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence -19.07 vs 0 placebo mg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wkd,b,c,e NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -1.3% (n=180) @ 104wkb,c,e NCT02849080 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain event count · % of participants | 13.7% (n=270) vs 8.3% (n=265) Insulin Degludec @ 52wk*d,b,c NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 37 Participants as posted show 1 more dose52% (n=271) vs 8.3% (n=265) Insulin Degludec @ 52wk* NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 141 Participants as posted | 45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*b,c Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted |
| HbA1c Less Than 7% event count · % of participants | 48.2% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mgf,b,c Yes NCT01541215 · Phase 3 · converted to % from 27 Participants as posted 2 other source trials89.1% (n=275) vs 69.7% (n=271) Insulin Degludec @ 52wk* Yes NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted 76.2% (n=273) vs 69.7% (n=271) Insulin Degludec @ 52wk* Yes NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 208 Participants as posted | 58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*f,b,c Yes NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted |
| HbA1c Less Than 7% event count · % of participants No placebo or comparator arm | 89.5% (n=200) @ 32wk*d,b,c,e NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 179 participants as posted show 1 more dose89.9% (n=189) @ 32wk* NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 170 participants as posted | 56.1% (n=180) @ 104wk*b,c,e Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 101 Participants as posted |
| HbA1c Less Than or Equal to 6.5 event count · % of participants | 44.6% (n=56) vs 25% (n=52) placebo @ 52wk*1.8 mgf,b,c Yes NCT01541215 · Phase 3 · converted to % from 25 Participants as posted | 39% (n=326) vs 23.2% (n=293) Other Oral Glucose-lowering Medication @ 52wk*f,b,c Yes NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 127 Participants as posted 1 other source trial33% (n=230) vs 12.2% (n=238) Sitagliptin @ 52wk* Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 76 Participants as posted |
| HDL Cholesterol ratio to baseline · ratio | 1.01 vs 1.02 Insulin Degludec ratio @ 26wkd,b,c NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose1.03 vs 1.02 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 1.01 vs 1.07 Empagliflozin 25 mg ratio @ 26wk14 mgb,c NCT02863328 · Phase 3 21 other source trials0.98 vs 0.99 Sitagliptin ratio @ 26wk14 mg NCT02607865 · Phase 3 0.97 vs 0.99 Sitagliptin ratio @ 26wk3 mg NCT02607865 · Phase 3 0.99 vs 0.99 Sitagliptin ratio @ 26wk7 mg NCT02607865 · Phase 3 1.02 vs 1.02 placebo ratio @ 26wk14 mg NCT02863419 · Phase 3 1.02 vs 1.02 placebo ratio @ 26wk14 mg NCT02827708 · Phase 3 0.98 vs 1.01 placebo ratio @ 26wk14 mg NCT03021187 · Phase 3 1 vs 1.01 placebo ratio @ 26wk3 mg NCT03021187 · Phase 3 0.98 vs 1.01 placebo ratio @ 26wk7 mg NCT03021187 · Phase 3 1.05 vs 1.02 placebo ratio NCT02692716 · Phase 3 1 vs 1 Sitagliptin ratio @ 26wk14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1.02 vs 1 Sitagliptin ratio @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1.01 vs 1 Sitagliptin ratio @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1.02 vs 1.04 placebo ratio @ 26wk14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1.03 vs 1.04 placebo ratio @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1.02 vs 1.04 placebo ratio @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.96 vs 1.03 placebo ratio @ 26wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.97 vs 1.03 placebo ratio @ 26wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.98 vs 1.03 placebo ratio @ 26wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 1 vs 0.99 Dulaglutide ratio @ 26wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.02 vs 0.99 Dulaglutide ratio @ 26wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.99 vs 0.99 Dulaglutide ratio @ 26wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| LDL Cholesterol ratio to baseline · ratio | 0.92 vs 1.01 Insulin Degludec ratio @ 26wkd,b,c NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.96 vs 1.01 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.96 vs 1.03 Empagliflozin 25 mg ratio @ 26wk14 mgb,c NCT02863328 · Phase 3 21 other source trials0.98 vs 1.02 Sitagliptin ratio @ 26wk14 mg NCT02607865 · Phase 3 1.02 vs 1.02 Sitagliptin ratio @ 26wk3 mg NCT02607865 · Phase 3 0.98 vs 1.02 Sitagliptin ratio @ 26wk7 mg NCT02607865 · Phase 3 0.95 vs 0.99 placebo ratio @ 26wk14 mg NCT02863419 · Phase 3 0.97 vs 1 placebo ratio @ 26wk14 mg NCT02827708 · Phase 3 0.93 vs 1.03 placebo ratio @ 26wk14 mg NCT03021187 · Phase 3 0.98 vs 1.03 placebo ratio @ 26wk3 mg NCT03021187 · Phase 3 0.93 vs 1.03 placebo ratio @ 26wk7 mg NCT03021187 · Phase 3 0.96 vs 0.97 placebo ratio NCT02692716 · Phase 3 0.98 vs 1.01 Sitagliptin ratio @ 26wk14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1.02 vs 1.01 Sitagliptin ratio @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.98 vs 1.01 Sitagliptin ratio @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.94 vs 1 placebo ratio @ 26wk14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1 vs 1 placebo ratio @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1 vs 1 placebo ratio @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.85 vs 1.03 placebo ratio @ 26wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.87 vs 1.03 placebo ratio @ 26wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.89 vs 1.03 placebo ratio @ 26wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.87 vs 0.88 Dulaglutide ratio @ 26wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.92 vs 0.88 Dulaglutide ratio @ 26wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.88 vs 0.88 Dulaglutide ratio @ 26wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| PPG Excursion absolute change · mmol/L | -0.747 vs -0.397 placebo mmol/L @ 52wk1.8 mgg,c NCT01541215 · Phase 3 2 other source trials-0.74 vs -0.27 Insulin Degludec mmol/L @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence -1.01 vs -0.27 Insulin Degludec mmol/L @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence | -0.6 vs -0.4 Empagliflozin 25 mg mmol/L @ 52wk14 mgg,c NCT02863328 · Phase 3 13 other source trials-0.7 vs -0.4 Sitagliptin mmol/L @ 52wk14 mg NCT02607865 · Phase 3 -0.4 vs -0.4 Sitagliptin mmol/L @ 52wk3 mg NCT02607865 · Phase 3 -0.4 vs -0.4 Sitagliptin mmol/L @ 52wk7 mg NCT02607865 · Phase 3 -0.5 vs -0.4 placebo mmol/L @ 52wk14 mg NCT02863419 · Phase 3 -0.7 vs -0.3 placebo mmol/L @ 52wk14 mg NCT03021187 · Phase 3 -0.3 vs -0.3 placebo mmol/L @ 52wk3 mg NCT03021187 · Phase 3 -0.7 vs -0.3 placebo mmol/L @ 52wk7 mg NCT03021187 · Phase 3 -2 vs -0.1 placebo mmol/L @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.5 vs -0.1 placebo mmol/L @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.9 vs -0.1 placebo mmol/L @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.9 vs -0.7 Dulaglutide mmol/L @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.6 vs -0.7 Dulaglutide mmol/L @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.8 vs -0.7 Dulaglutide mmol/L @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -1.95 vs -3.35 placebo mmHg @ 26wkb,c NCT02964247 · Phase 3 · registry result, not featured evidence | -4 vs -2 placebo mmHg @ 26wk14 mgd,b,c NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-2 vs -2 placebo mmHg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1 vs -2 placebo mmHg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L | -2.309 vs -0.748 placebo mmol/L @ 52wk1.8 mgg,c NCT01541215 · Phase 3 | -2.3 vs -2.1 Empagliflozin 25 mg mmol/L @ 52wk14 mgg,c NCT02863328 · Phase 3 13 other source trials-1.8 vs -1.4 Sitagliptin mmol/L @ 52wk14 mg NCT02607865 · Phase 3 -1.3 vs -1.4 Sitagliptin mmol/L @ 52wk3 mg NCT02607865 · Phase 3 -1.5 vs -1.4 Sitagliptin mmol/L @ 52wk7 mg NCT02607865 · Phase 3 -2.2 vs -0.9 placebo mmol/L @ 52wk14 mg NCT02863419 · Phase 3 -2 vs -0.9 placebo mmol/L @ 52wk14 mg NCT03021187 · Phase 3 -1.6 vs -0.9 placebo mmol/L @ 52wk3 mg NCT03021187 · Phase 3 -1.7 vs -0.9 placebo mmol/L @ 52wk7 mg NCT03021187 · Phase 3 -3.1 vs 0 placebo mmol/L @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1.7 vs 0 placebo mmol/L @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -2.2 vs 0 placebo mmol/L @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -3.3 vs -2.6 Dulaglutide mmol/L @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence -1.7 vs -2.6 Dulaglutide mmol/L @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -2.5 vs -2.6 Dulaglutide mmol/L @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Total Cholesterol ratio to baseline · ratio | 0.94 vs 0.99 Insulin Degludec ratio @ 26wkd,b,c NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.97 vs 0.99 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.96 vs 1.02 Empagliflozin 25 mg ratio @ 26wk14 mgb,c NCT02863328 · Phase 3 21 other source trials0.97 vs 1 Sitagliptin ratio @ 26wk14 mg NCT02607865 · Phase 3 1 vs 1 Sitagliptin ratio @ 26wk3 mg NCT02607865 · Phase 3 0.98 vs 1 Sitagliptin ratio @ 26wk7 mg NCT02607865 · Phase 3 0.96 vs 0.99 placebo ratio @ 26wk14 mg NCT02863419 · Phase 3 0.97 vs 1 placebo ratio @ 26wk14 mg NCT02827708 · Phase 3 0.95 vs 1.03 placebo ratio @ 26wk14 mg NCT03021187 · Phase 3 0.99 vs 1.03 placebo ratio @ 26wk3 mg NCT03021187 · Phase 3 0.95 vs 1.03 placebo ratio @ 26wk7 mg NCT03021187 · Phase 3 0.97 vs 0.98 placebo ratio NCT02692716 · Phase 3 0.96 vs 0.99 Sitagliptin ratio @ 26wk14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1 vs 0.99 Sitagliptin ratio @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.96 vs 0.99 Sitagliptin ratio @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.94 vs 1 placebo ratio @ 26wk14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.99 vs 1 placebo ratio @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.98 vs 1 placebo ratio @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.89 vs 1 placebo ratio @ 26wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.92 vs 1 placebo ratio @ 26wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.93 vs 1 placebo ratio @ 26wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.91 vs 0.92 Dulaglutide ratio @ 26wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.96 vs 0.92 Dulaglutide ratio @ 26wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.91 vs 0.92 Dulaglutide ratio @ 26wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Triglyceride ratio to baseline · ratio | 0.88 vs 0.82 Insulin Degludec ratio @ 26wkd,b,c NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.9 vs 0.82 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.88 vs 0.9 Empagliflozin 25 mg ratio @ 26wk14 mgb,c NCT02863328 · Phase 3 21 other source trials0.92 vs 0.97 Sitagliptin ratio @ 26wk14 mg NCT02607865 · Phase 3 0.99 vs 0.97 Sitagliptin ratio @ 26wk3 mg NCT02607865 · Phase 3 0.96 vs 0.97 Sitagliptin ratio @ 26wk7 mg NCT02607865 · Phase 3 0.89 vs 1.01 placebo ratio @ 26wk14 mg NCT02863419 · Phase 3 0.87 vs 0.95 placebo ratio @ 26wk14 mg NCT02827708 · Phase 3 0.91 vs 0.99 placebo ratio @ 26wk14 mg NCT03021187 · Phase 3 0.97 vs 0.99 placebo ratio @ 26wk3 mg NCT03021187 · Phase 3 0.92 vs 0.99 placebo ratio @ 26wk7 mg NCT03021187 · Phase 3 0.92 vs 0.97 placebo ratio NCT02692716 · Phase 3 0.86 vs 0.91 Sitagliptin ratio @ 26wk14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.96 vs 0.91 Sitagliptin ratio @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.86 vs 0.91 Sitagliptin ratio @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.87 vs 0.93 placebo ratio @ 26wk14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.96 vs 0.93 placebo ratio @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.9 vs 0.93 placebo ratio @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0.93 vs 0.87 placebo ratio @ 26wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 1.03 vs 0.87 placebo ratio @ 26wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.94 vs 0.87 placebo ratio @ 26wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.96 vs 0.93 Dulaglutide ratio @ 26wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.03 vs 0.93 Dulaglutide ratio @ 26wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.91 vs 0.93 Dulaglutide ratio @ 26wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| VLDL Cholesterol ratio to baseline · ratio | 0.9 vs 0.84 Insulin Degludec ratio @ 26wkd,b,c NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.92 vs 0.84 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.89 vs 0.91 Empagliflozin 25 mg ratio @ 26wk14 mgb,c NCT02863328 · Phase 3 13 other source trials0.91 vs 0.97 Sitagliptin ratio @ 26wk14 mg NCT02607865 · Phase 3 0.99 vs 0.97 Sitagliptin ratio @ 26wk3 mg NCT02607865 · Phase 3 0.96 vs 0.97 Sitagliptin ratio @ 26wk7 mg NCT02607865 · Phase 3 0.9 vs 1.02 placebo ratio @ 26wk14 mg NCT02863419 · Phase 3 0.94 vs 0.98 Sitagliptin ratio @ 26wk14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1.05 vs 0.98 Sitagliptin ratio @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.94 vs 0.98 Sitagliptin ratio @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.93 vs 0.87 placebo ratio @ 26wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 1.02 vs 0.87 placebo ratio @ 26wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.94 vs 0.87 placebo ratio @ 26wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.96 vs 0.93 Dulaglutide ratio @ 26wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.03 vs 0.93 Dulaglutide ratio @ 26wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.92 vs 0.93 Dulaglutide ratio @ 26wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Waist Circumference Change absolute change · cm | 2.5 vs 3.4 Insulin Degludec cm @ 52wkd,b,c NCT02607306 · Phase 3 · registry result, not featured evidence show 1 more dose-1.1 vs 3.4 Insulin Degludec cm @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence | -3.7 vs -2.9 Empagliflozin 25 mg cm @ 52wk14 mgb,c NCT02863328 · Phase 3 14 other source trials-2.6 vs -0.5 Sitagliptin cm @ 52wk14 mg NCT02607865 · Phase 3 -1.3 vs -0.5 Sitagliptin cm @ 52wk3 mg NCT02607865 · Phase 3 -2.3 vs -0.5 Sitagliptin cm @ 52wk7 mg NCT02607865 · Phase 3 -4.4 vs -1.7 placebo cm @ 52wk14 mg NCT02863419 · Phase 3 -4 vs 0.3 placebo cm @ 52wk14 mg NCT03021187 · Phase 3 -0.8 vs 0.3 placebo cm @ 52wk3 mg NCT03021187 · Phase 3 -2.3 vs 0.3 placebo cm @ 52wk7 mg NCT03021187 · Phase 3 -2.6 vs -0.7 Sitagliptin cm @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence -2.7 vs -0.9 placebo cm @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.2 vs -0.9 placebo cm @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1 vs -0.9 placebo cm @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1.7 vs 0.7 Dulaglutide cm @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.1 vs 0.7 Dulaglutide cm @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.8 vs 0.7 Dulaglutide cm @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Weight percent change · % of baseline | -7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkb,c,h NCT01234649 · Phase 3 · registry result, not featured evidence · combination | -3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wkb,c,h NCT02849080 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 21.1%1.8 mg dailyi NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence | 6.9%14 mgj NCT02906930 · Phase 3 show 39 more results8%7 mg NCT02906930 · Phase 3 3.4%3 mg NCT02906930 · Phase 3 2.7%14 mg NCT02863328 · Phase 3 5.8%14 mg NCT02607865 · Phase 3 6.4%7 mg NCT02607865 · Phase 3 7.1%3 mg NCT02607865 · Phase 3 2.8%14 mg NCT02863419 · Phase 3 3.1%14 mg NCT02827708 · Phase 3 3.3%14 mg NCT03021187 · Phase 3 4.9%7 mg NCT03021187 · Phase 3 5.4%3 mg NCT03021187 · Phase 3 1.5% NCT03914326 · Phase 3 0.3% NCT02692716 · Phase 3 11.8% NCT05035082 · Phase 4 · registry result, not featured evidence 5.4%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 5.6%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.4%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 7.2%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 5%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.6%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 2.1%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 2.3%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.5%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 2.3%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 11.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 11.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 5.7%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 8.6%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 12%1.8 mg dailyi NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence | —14 mgj NCT02906930 · Phase 3 show 39 more results—7 mg NCT02906930 · Phase 3 —3 mg NCT02906930 · Phase 3 —14 mg NCT02863328 · Phase 3 —14 mg NCT02607865 · Phase 3 —7 mg NCT02607865 · Phase 3 —3 mg NCT02607865 · Phase 3 —14 mg NCT02863419 · Phase 3 —14 mg NCT02827708 · Phase 3 —14 mg NCT03021187 · Phase 3 —7 mg NCT03021187 · Phase 3 —3 mg NCT03021187 · Phase 3 — NCT03914326 · Phase 3 — NCT02692716 · Phase 3 — NCT05035082 · Phase 4 · registry result, not featured evidence —14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —14 mg NCT04017832 · Phase 3 · registry result, not featured evidence —7 mg NCT04017832 · Phase 3 · registry result, not featured evidence —3 mg NCT04017832 · Phase 3 · registry result, not featured evidence —14 mg NCT04109547 · Phase 3 · registry result, not featured evidence —7 mg NCT04109547 · Phase 3 · registry result, not featured evidence —3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence —14 mg NCT03018028 · Phase 3 · registry result, not featured evidence —7 mg NCT03018028 · Phase 3 · registry result, not featured evidence —3 mg NCT03018028 · Phase 3 · registry result, not featured evidence —14 mg NCT03015220 · Phase 3 · registry result, not featured evidence —7 mg NCT03015220 · Phase 3 · registry result, not featured evidence —3 mg NCT03015220 · Phase 3 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —20 mg NCT01923181 · Phase 2 · registry result, not featured evidence —10 mg NCT01923181 · Phase 2 · registry result, not featured evidence —5 mg NCT01923181 · Phase 2 · registry result, not featured evidence —2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.6%1.8 mg dailyi NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence | 1.1%14 mgj NCT02906930 · Phase 3 show 39 more results1.7%7 mg NCT02906930 · Phase 3 2.9%3 mg NCT02906930 · Phase 3 6.6%14 mg NCT02863328 · Phase 3 9.5%14 mg NCT02607865 · Phase 3 10.1%7 mg NCT02607865 · Phase 3 13.7%3 mg NCT02607865 · Phase 3 10.9%14 mg NCT02863419 · Phase 3 10.4%14 mg NCT02827708 · Phase 3 6.6%14 mg NCT03021187 · Phase 3 10.5%7 mg NCT03021187 · Phase 3 13.6%3 mg NCT03021187 · Phase 3 47.9% NCT03914326 · Phase 3 18.9% NCT02692716 · Phase 3 10.2% NCT05035082 · Phase 4 · registry result, not featured evidence 9.9%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.2%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 10.7%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 3%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.9%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 7.7%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 4.6%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 9.5%Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence 14.2%Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence 9%Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 0%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 4.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 5.4%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 3%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 6.9%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 0%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 1.4%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1.8 mg dailyi nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence | 14 mgj nausea 16% (placebo 5.6%) vomiting 6.9% (placebo 2.2%) decreased appetite 5.1% (placebo 0.6%) NCT02906930 · Phase 3 show 38 more results7 mg nasopharyngitis 6.3% (placebo 3.4%) headache 5.7% (placebo 5.1%) diarrhoea 5.1% (placebo 2.2%) NCT02906930 · Phase 3 3 mg diarrhoea 8.6% (placebo 2.2%) nausea 8% (placebo 5.6%) nasopharyngitis 5.7% (placebo 3.4%) NCT02906930 · Phase 3 14 mg nausea 19.3% (placebo 3.5%) diarrhoea 15.1% (placebo 7.7%) nasopharyngitis 14.4% (placebo 10.6%) NCT02863419 · Phase 3 14 mg nausea 19% (placebo 7.5%) constipation 11.7% (placebo 3.7%) vomiting 11.7% (placebo 1.2%) NCT02827708 · Phase 3 14 mg nausea 22.7% (placebo 7.1%) diarrhoea 14.4% (placebo 6%) decreased appetite 12.7% (placebo 1.1%) NCT03021187 · Phase 3 7 mg nausea 16.6% (placebo 7.1%) diarrhoea 12.2% (placebo 6%) nasopharyngitis 11.6% (placebo 14.7%) NCT03021187 · Phase 3 3 mg nasopharyngitis 14.7% (placebo 14.7%) nausea 11.4% (placebo 7.1%) diarrhoea 8.7% (placebo 6%) NCT03021187 · Phase 3 diabetic retinopathy 19.5% (placebo 19.3%) covid-19 15.7% (placebo 16.1%) nausea 7.1% (placebo 1.3%) NCT03914326 · Phase 3 14 mg once daily nausea 18% diarrhoea 12.4% covid-19 11.8% NCT04707469 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 27.3% vomiting 18.2% diarrhoea 14.2% NCT04707469 · Phase 3 · registry result, not featured evidence 25 mg once daily nausea 27.2% vomiting 17% diarrhoea 12.9% NCT04707469 · Phase 3 · registry result, not featured evidence 14 mg diarrhoea 13.3% nausea 12.2% decreased appetite 9.4% NCT04017832 · Phase 3 · registry result, not featured evidence 7 mg nausea 10.9% diarrhoea 8.9% decreased appetite 8.4% NCT04017832 · Phase 3 · registry result, not featured evidence 3 mg nausea 10% diarrhoea 8.3% upper respiratory tract infection 7.2% NCT04017832 · Phase 3 · registry result, not featured evidence 14 mg decreased appetite 10.9% (placebo 0%) diarrhoea 9.3% (placebo 1.5%) upper respiratory tract infection 7% (placebo 4.6%) NCT04109547 · Phase 3 · registry result, not featured evidence 7 mg diarrhoea 9.2% (placebo 1.5%) upper respiratory tract infection 9.2% (placebo 4.6%) lipase increased 8.5% (placebo 0%) NCT04109547 · Phase 3 · registry result, not featured evidence 3 mg upper respiratory tract infection 8.5% (placebo 4.6%) lipase increased 5.4% (placebo 0%) nausea 4.6% (placebo 1.5%) NCT04109547 · Phase 3 · registry result, not featured evidence nausea 20.9% nasopharyngitis 10.3% headache 9.9% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 22.9% nasopharyngitis 13.4% diarrhoea 11.5% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 17% diarrhoea 10% nasopharyngitis 7% NCT02849080 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 18.8% (placebo 28.6%) constipation 12.5% (placebo 6.1%) decreased appetite 12.5% (placebo 0%) NCT03018028 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 16.3% (placebo 28.6%) constipation 12.2% (placebo 6.1%) nausea 10.2% (placebo 2%) NCT03018028 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 20.4% (placebo 28.6%) constipation 10.2% (placebo 6.1%) periarthritis 10.2% (placebo 4.1%) NCT03018028 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 30% constipation 15.4% nausea 9.2% NCT03015220 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 29.5% constipation 12.1% decreased appetite 9.1% NCT03015220 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 26% constipation 9.2% influenza 6.9% NCT03015220 · Phase 3 · registry result, not featured evidence 40 mg nausea 33.8% (placebo 1.4%) vomiting 19.7% (placebo 4.2%) decreased appetite 14.1% (placebo 1.4%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 35.7% (placebo 1.4%) vomiting 22.9% (placebo 4.2%) diarrhoea 17.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 32.9% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 15.7% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 20 mg nausea 35.7% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 17.1% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 10 mg nausea 33.3% (placebo 1.4%) diarrhoea 23.2% (placebo 9.9%) vomiting 20.3% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 5 mg nausea 14.3% (placebo 1.4%) headache 12.9% (placebo 5.6%) diarrhoea 10% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 2.5 mg nausea 12.9% (placebo 1.4%) nasopharyngitis 8.6% (placebo 12.7%) diarrhoea 7.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 32 weeks versus 104 weeks.
- fTrial phases differ: Phase 3 versus Phase 4.
- gPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
- hAssessment timepoints differ: 84 weeks versus 104 weeks.
- iPopulation comparability has not been reviewed for 32 of these studies.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
show 3 more results
show 1 more result
show 3 more results
show 1 more result
show 8 more results
+ 107 further endpoints in the CSV export.
Semaglutide (Rybelsus)
show 11 more results
show 9 more results
show 2 more results
show 11 more results
show 10 more results
show 10 more results
show 36 more results
show 39 more results
show 1 more result
show 10 more results
show 10 more results
show 12 more results
+ 106 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · Semaglutide (Rybelsus)'s landscape